Literature DB >> 17509993

Correlation of serum TNF-alpha levels and histologic liver injury scores in pediatric nonalcoholic fatty liver disease.

Melania Manco1, Matilde Marcellini, Germana Giannone, Valerio Nobili.   

Abstract

We tested the power of tumor necrosis factor (TNF)-alpha and/or leptin in predicting the degree of liver involvement in children with nonalcoholic fatty liver disease (NAFLD). We measured serum levels of TNF-alpha and leptin and computed NAFLD activity score (NAS) (NAS >or= 5, diagnostic of nonalcoholic steatohepatitis [NASH]) in 72 consecutive biopsy-proven NAFLD cases (training and validation sets, 36 cases each). Univariate analysis evaluated variables significantly associated with a diagnostic NAS. Receiver operating characteristic (ROC) curve analysis assessed the diagnostic value of selected variables in predicting a NAS of 5 or more.TNF-alpha (P < .0001), leptin (P = .001); triglycerides (P = .013), and alkaline phosphatase (P = .046) levels were significantly associated with a NAS of 5 or more. TNF-alpha and leptin levels predicted the risk of NAS of 5 or more. ROC analyses defined cutoff values for TNF-alpha, leptin, and risk score. They identified 90%, 83%, and 83% of the cases, respectively, with a NAS of 5 or more (true-positive cases) from the validation set.TNF-alpha alone or combined with leptin in a simple risk score can accurately predict a NAS of 5 or more. TNF-alpha seems to be a specific laboratory marker of NASH.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17509993     DOI: 10.1309/6VJ4DWGYDU0XYJ8Q

Source DB:  PubMed          Journal:  Am J Clin Pathol        ISSN: 0002-9173            Impact factor:   2.493


  66 in total

1.  Atherogenic dyslipidemia and cardiovascular risk in children with nonalcoholic fatty liver disease.

Authors:  Naim Alkhouri; Christine Carter-Kent; Michael Elias; Ariel E Feldstein
Journal:  Clin Lipidol       Date:  2011-06-01

2.  Fatty liver disease in children: eat now pay later.

Authors:  Ruth M L De Bruyne; Emer Fitzpatrick; Anil Dhawan
Journal:  Hepatol Int       Date:  2010-01-29       Impact factor: 6.047

3.  Nonalcoholic fatty liver disease as trigger of cardiovascular and metabolic complication in metabolic syndrome.

Authors:  Luca Miele; Giovanni Gasbarrini; Valentina Giorgio; Antonio Gasbarrini; Antonio Grieco
Journal:  Intern Emerg Med       Date:  2015-11-24       Impact factor: 3.397

Review 4.  Noninvasive biomarkers in non-alcoholic fatty liver disease: current status and a glimpse of the future.

Authors:  Emer Fitzpatrick; Anil Dhawan
Journal:  World J Gastroenterol       Date:  2014-08-21       Impact factor: 5.742

5.  Usefulness of differentiating metabolic syndrome into visceral fat type and subcutaneous fat type using ultrasonography in Japanese males.

Authors:  Masahiro Sogabe; Toshiya Okahisa; Shingo Hibino; Akira Yamanoi
Journal:  J Gastroenterol       Date:  2011-11-09       Impact factor: 7.527

Review 6.  Inflammation and fibrogenesis in steatohepatitis.

Authors:  Hideki Fujii; Norifumi Kawada
Journal:  J Gastroenterol       Date:  2012-02-07       Impact factor: 7.527

7.  Methods to improve the noninvasive diagnosis and assessment of disease severity in children with suspected nonalcoholic fatty liver disease (NAFLD): Study design.

Authors:  Bryan Rudolph; Nicole Bjorklund; Nadia Ovchinsky; Debora Kogan-Liberman; Adriana Perez; Mark Liszewski; Terry L Levin; Michelle Ewart; Qiang Liu; Xiaonan Xue; Shankar Viswanathan; Howard D Strickler
Journal:  Contemp Clin Trials       Date:  2018-10-27       Impact factor: 2.226

Review 8.  The Riddle of Nonalcoholic Fatty Liver Disease: Progression From Nonalcoholic Fatty Liver to Nonalcoholic Steatohepatitis.

Authors:  Mithun Sharma; Shasikala Mitnala; Ravi K Vishnubhotla; Rathin Mukherjee; Duvvur N Reddy; Padaki N Rao
Journal:  J Clin Exp Hepatol       Date:  2015-02-16

9.  Serum adipokines might predict liver histology findings in non-alcoholic fatty liver disease.

Authors:  Raika Jamali; Mohsen Razavizade; Abbas Arj; Mohammad Hossein Aarabi
Journal:  World J Gastroenterol       Date:  2016-06-07       Impact factor: 5.742

10.  5-cholesten-3β,25-diol 3-sulfate decreases lipid accumulation in diet-induced nonalcoholic fatty liver disease mouse model.

Authors:  Leyuan Xu; Jin Koung Kim; Qianming Bai; Xin Zhang; Genta Kakiyama; Hae-Ki Min; Arun J Sanyal; William M Pandak; Shunlin Ren
Journal:  Mol Pharmacol       Date:  2012-12-20       Impact factor: 4.436

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.